This was sent to me and I think that it is really interesting it is about a new drug that is used to treat Type 2 Diabetes and it is amazing:
When food enters the body, the level of blood sugar rises. Rising blood sugar levels signal the intestines to release incretin hormones (GLP-1). These hormones signal the pancreas to release insulin. Insulin balances blood sugar levels by converting glucose into energy, and it signals the liver to stop producing glucose. DPP-4 breaks down incretin, once blood sugar has been stabilized, stopping the release of insulin.
That is how the process works in someone without type 2 diabetes. But for people who do have type 2 diabetes, blood sugar levels are too high and they often require medication to help control blood sugar.
Januvia and Byetta
Januvia (sitagliptin) is an oral prescription medication that was approved by the Food and Drug Administration (FDA) in 2006 for the treatment of type 2 diabetes. It quickly became Merck & Co.’s fastest-growing medication, and is only now starting to see sales numbers flag. It belongs to a newer class of drugs called DPP-4 inhibitors. Januvia, similar to drugs in its class, prevents DPP-4 from breaking down incretin hormones—meaning incretin stays in the bloodstream longer, continuing to stimulate the pancreas to release insulin and lower blood sugar.
Januvia can be used alone, but is also used in conjunction with other medications or insulin injections. Januvia is often prescribed with an injectable medication called Byetta (exenatide), which was approved by the FDA in 2005 for the treatment of type 2 diabetes.
Byetta is a synthetic protein that is similar to incretin, the hormone released from the digestive tract that regulates insulin. It is also known to slow the appetite and digestion, contributing to weight loss.
In 2007, a combination of Januvia and metformin was released called Janumet. Metformin has a long history in treating type 2 diabetes, with minimal risk of adverse side effects.
Side Effects of Januvia
The FDA has received hundreds of reports of severe side effects associated with Januvia and Byetta. The most serious side effect is the heightened risk of pancreatitis and pancreatic cancer, which can be fatal.
Using Januvia and Byetta doubles the risk of pancreatitis, which is the painful inflammation of the pancreas. The condition causes the body to attack the pancreas and other nearby organs and tissues. Its symptoms can include nausea or vomiting, fever, increased heart rate and abdominal or lower back pain.
Acute pancreatitis, also called sudden-onset pancreatitis, constitutes a medical emergency. Necrotizing pancreatitis describes the unfortunate event in which the body’s digestive enzymes actually begin to digest pancreatic tissue.
Pancreatic risks increase the longer these medications are used. Pancreatic lesions form, and tumors can grow. Pancreatic cancer is difficult to diagnose without removing the pancreas, so tumors can grow hidden from patients and doctors.
Because it is seldom diagnosed in stages early enough for treatment, pancreatic cancer is almost always fatal. The American Cancer Society reports an average survival rate of less than two years after diagnosis, and only 4 percent of patients live longer than 5 years. Merck now faces lawsuits filed by patients or families of patients who developed pancreatic diseases after using Januvia. The FDA is investigating the link between Januvia and Byetta, and pancreatic complications.
Linda Grayling is a content writer at Drugwatch.com. She enjoys researching the latest studies and news from the medical field. To learn more about medication safety updates by checking out Drugwatch.com on Facebook.
I hope you liked that as much as I did. I anyone has any questions then please feel free to ask and if I dont know the answer I’ll pass your question on to someone who does.
Thank you Linda Grayling for writing this piece it is amazing.